RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13

BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 7, RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) and set a price target of $13.00.

The same day, the company also announced the appointment of Babar Ghias as Chief Financial Officer and Head of Corporate Development.

With extensive experience from his prior roles at AvenCell Therapeutics and Paragon Biosciences, the company expects his appointment to bolster BioCryst Pharmaceutical Inc.’s (NASDAQ:BCRX) leadership team and support its goals of growth acceleration and increase in value creation.

Management also sees this strategic move as instrumental for BioCryst Pharmaceutical Inc.’s (NASDAQ:BCRX) financial discipline and operational excellence, supporting its optimistic growth plans.

BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) is a biotechnology company that provides structure-guided drug design to develop oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases.

While we acknowledge the potential of BCRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.